Life Science Partner Recruits Ricardo Mesa-Tejada, MD, to Clinical Leadership at Aureon Biosciences

Founder and Director of Immunocytochemistry Laboratory at MetPath/Quest

Life Science Partner announces the recruitment of Dr. Ricardo Mesa-Tejada, a recognized leader in the field of anatomic pathology to become vice president, pathology, Aureon Biosciences Corporation.  Aureon is a Yonkers, New York-based company enabling personalized patient care utilizing a systems pathology approach to develop predictive clinical tests for cancer care as well as to enable biopharmaceutical research and development.

Dr. Mesa-Tejada will lead the team of specialized anatomical pathologists interrogating and analyzing tissue to provide the first comprehensive and fully integrated view of the progression of cancer by studying multiple molecular pathways of disease as well as micro-anatomic imaging.  By utilizing state-of-the-art informatics, Dr. Mesa-Tejada will be able to provide referring physicians some of the first predictive tests for cancer by integrating molecular pathology and clinical informatics.

“Ricardo is the prototype of physician-scientist who has a keen interest in harnessing new technologies for better patient care,” noted Tom Callaway, MD, founder and president of Life Science Partner.  “He was drawn to Aureon by its intersection of clinical informatics, image analysis and molecular diagnostics to greatly improve the treatment planning of complicated diseases like prostate cancers.”

Dr. Mesa-Tejada is uniquely qualified due to his significant research and clinical service as a pathologist at New York’s Columbia-Presbyterian Medical Center.  A pioneer in integrating technologies for better patient care, he established the immunocytochemistry laboratory at MetPath in 1987, and remained as either an employee or consultant through its acquisition and integration into Quest Diagnostics.  He remained as director of research in anatomic pathology at the company until 1997.  Until he joined Aureon, he was a consultant to Thieme, an investment banking firm focused on the life sciences.

Dr. Mesa-Tejada received his MD from University of Madrid, completed his residency in Pathology at Columbia-Presbyterian, and was a fellow in OB/GYN Pathology in 1976.